At the news
? NEUTRALIMPACT 3/10 PRESS-RELEASE filed Mar 10, 2026 at 07:30 ET
Palvella Therapeutics launched the 'BEYOND mLM' disease awareness campaign and website (BEYONDmLM.com) to educate patients, caregivers, and healthcare providers about microcystic lymphatic malformations (microcystic LMs), a rare and debilitating condition with no FDA-approved therapies. The campaign was developed in collaboration with leading nonprofit organizations and clinical experts in the vascular anomalies community.
- Palvella launched BEYONDmLM.com, an educational campaign and website focused on microcystic lymphatic malformations (microcystic LMs).
- The campaign was developed in partnership with five key nonprofit organizations: CaNVAS, LGDA, LE&RN, PeDRA, and VAccess.org.
- Microcystic LMs affect over 30,000 diagnosed patients in the U.S. and are characterized by malformed lymphatic vessels causing chronic leakage, bleeding, and recurrent infections.
- There are currently no FDA-approved treatments for microcystic LMs.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access